key: cord-0939863-2xn0jmq4
authors: Martin‐Vicente, María; Almansa, Raquel; Martínez, Isidoro; Tedim, Ana P.; Bustamante, Elena; Tamayo, Luis; Aldecoa, César; Gómez, José Manuel; Renedo, Gloria; Berezo, Jose Ángel; Cedeño, Jamil Antonio; Mamolar, Nuria; García Olivares, Pablo; Herrán‐Monge, Rubén; Cicuendez, Ramón; Enríquez, Pedro; Ortega, Alicia; Jorge, Noelia; Doncel, Cristina; de la Fuente, Amanda; Bustamante‐Munguira, Juan; Muñoz‐Gómez, María José; González‐Rivera, Milagros; Puertas, Carolina; Más, Vicente; Vázquez, Mónica; Pérez‐García, Felipe; Rico‐Feijoo, Jesús; Martín, Silvia; Motos, Anna; Fernandez‐Barat, Laia; Eiros, Jose María; Dominguez‐Gil, Marta; Ferrer, Ricard; Barbé, Ferrán; Trapiello, Wysali; Kelvin, David J.; Bermejo‐Martin, Jesús F.; Resino, Salvador; Torres, Antoni
title: Low anti‐SARS‐CoV‐2 S antibody levels predict increased mortality and dissemination of viral components in the blood of critical COVID‐19 patients
date: 2021-10-05
journal: J Intern Med
DOI: 10.1111/joim.13386
sha: 156b62c253679702cbee64deaae946b29c747cd1
doc_id: 939863
cord_uid: 2xn0jmq4

BACKGROUND: Anti‐SARS‐CoV‐2 S antibodies prevent viral replication. Critically ill COVID‐19 patients show viral material in plasma, associated with a dysregulated host response. If these antibodies influence survival and viral dissemination in ICU‐COVID patients is unknown. PATIENTS/METHODS: We studied the impact of anti‐SARS‐CoV‐2 S antibodies levels on survival, viral RNA‐load in plasma, and N‐antigenaemia in 92 COVID‐19 patients over ICU admission. RESULTS: Frequency of N‐antigenaemia was >2.5‐fold higher in absence of antibodies. Antibodies correlated inversely with viral RNA‐load in plasma, representing a protective factor against mortality (Adjusted HR [CI 95%], p): (S IgM [AUC ≥ 60]: 0.44 [0.22; 0.88], 0.020); (S IgG [AUC ≥ 237]: 0.31 [0.16; 0.61], <0.001). Viral RNA‐load in plasma and N‐antigenaemia predicted increased mortality: (N1‐viral load [≥ 2.156 copies/ml]: 2.25 [1.16; 4.36], 0.016); (N‐antigenaemia: 2.45 [1.27; 4.69], 0.007). CONCLUSIONS: Low anti‐SARS‐CoV‐2 S antibody levels predict mortality in critical COVID‐19. Our findings support that these antibodies contribute to prevent systemic dissemination of SARS‐CoV‐2.

Anti-SARS-CoV-2 spike (S) antibodies bind to multiple domains in this viral protein [1] . Host antibodies directed at the receptor binding domain (RBD ) mediate inhibition of viral attachment to cell surface receptors [2] . Therefore, anti-S antibodies could play a role in reducing viral replication during an ongoing acute infection by interfering with virus entry into a cell. Interestingly, whether levels of host-produced endogenous antibodies against the S protein could influence mortality risk in severe COVID-19 has not been sufficiently studied to the present date.

Recent works from our group and others have demonstrated the importance of SARS-CoV-2 RNAemia [3] [4] [5] and SARS-CoV-2 antigenaemia as markers of severity in COVID-19 [6] . The presence of viral RNA and proteins in plasma could represent a surrogated marker of poor viral control. On top of this, viral RNAemia and antigenaemia associate with dysregulated host responses to the infection caused by SARS-CoV-2 [3, 7] . It is necessary to elucidate whether anti-SARS-CoV-2 S antibodies could influence the dissemination of viral genomic material or viral proteins at the systemic level.

In this work, we profiled the concentration of anti-SARS-CoV-2 S IgM and IgG antibodies in the plasma of patients with COVID-19 in the first 24 h following admission to the ICU. We evaluated the association between antibody levels with the concentration of viral RNA and the presence of SARS-CoV-2 nucleoprotein (N) protein in plasma. In parallel, we assessed the impact of antibody levels, viral RNA load and antigenaemia on the mortality risk of these patients.

We recruited 92 critically ill adult patients with a positive nasopharyngeal swab polymerase chain reaction (PCR) test for SARS-CoV-2 from 16th March to 15th April 2020, during the first pandemic wave, at Hospital Universitario Río Hortega, Hospital Clínico Universitario (Valladolid); Hospital Gregorio Marañón, Hospital Príncipe de Asturias (Madrid), Spain. We obtained EDTA plasma in the first 24 h following admission to the ICU. The study was approved by the "Comite de Etica de la Investigacion con Medicamentos del Area de Salud # These authors contributed equally to this work.

de Salamanca", code PI 2020 03 452. Informed consent was obtained orally when clinically possible. In the remaining cases, the informed consent waiver was authorized by the Ethics committee.

We quantified SARS-CoV-2 RNA in plasma using the Bio-Rad SARS-CoV-2 droplet digital PCR kit (CA, USA) (File S1). Our team developed a specific immunoassay to quantify anti-SARS-CoV-2 S IgG and IgM antibodies in plasma (File S1). We evaluated the presence/absence of N antigen of SARS-CoV-2 in plasma using the Panbio COVID-19 Ag Rapid Test Device from Abbott (Chicago, IL, USA).

Statistical analysis was performed using IBM SPSS Statistics 25.0 (SPSS INC, Armonk, NY, U.S.A). The level of significance was fixed at 0.05 (twotailed). Differences between independent groups were assessed using the chi-square test or Fisher's Exact Test for categorical variables and the Mann-Whitney U test for continuous variables.

The Kaplan-Meier method was used to calculate survival probabilities and the log-rank test to compare groups. We also used Cox proportionalhazards models to estimate the risk of dying, adjusted by the significant covariates at baseline resulting from the comparison between survivors and non-survivors (full description in File S1). The outcome was 30-day mortality following ICU admission. (Table 1) : Patients who died were older than those who survived. In addition, patients who died had increased frequency of arterial hypertension and type-2 diabetes, higher glucose and creatinine levels, decreased concentrations of platelets and monocytes, and higher APACHE and SOFA scores. Patients who died received more often betainterferon than those who survived.

Ten patients (of the total cohort) had no detectable levels in the plasma of anti-SARS-CoV-2 S IgG, and 13 had no detectable levels of anti-SARS-CoV-2 S IgM. Patients who died showed more often absence/lower levels of anti-SARS-CoV-2 S IgM and IgG than those who survived by day 

In contrast to that observed for antibodies, nonsurvivors showed more frequently the presence of antigenaemia ( Figure 1 , panel 1) along with higher viral RNA loads in plasma (Figure 1, panel 2) .

Frequency of N-antigenaemia was >2.5 fold higher in patients with no anti-SARS-CoV-2 S antibodies than in those patients who presented detectable antibodies (anti-SARS-CoV-2 S IgM: 77%/25%; IgG: 70%/28%) (Figure 1, panel 3) . In turn, levels of anti-S antibodies correlated inversely with viral RNA load in plasma: anti-SARS-CoV-2 S IgM / N1 (copies/ml) (r = −0.34, p < 0.001); anti-SARS-CoV-2 S IgM / N2 (copies/ml) (r = −0.37, p < 0.001) ( Figure 1, panel 4) ; anti-SARS-CoV-2 S IgG / N1 (copies/ml) (r = −0.45, p < 0.001); anti-SARS-CoV-2 S IgG / N2 (copies/ml) (r = −0.48, p < 0.001) (Figure 1, panel 4) .

Multivariate analysis demonstrated that the absence/low levels of anti-SARS-CoV-2 S IgM and IgG was an independent risk factor for mortality at day 30 following ICU admission ( Figure 2 ). In turn, the multivariate analysis evidenced that the presence of N-antigenaemia and high viral RNA loads predicted also increased mortality (Figure 2 ). When levels of anti-SARS-CoV-2 S antibodies, viral RNA load and antigenaemia were simultaneously introduced in the multivariate analysis, anti-S IgG, anti-S IgM and viral RNA concentrations in plasma still predicted mortality (File S2). Kaplan-Meier

analysis evidenced that low antibody levels, high viral RNA loads in plasma, or the presence of N-antigenaemia translated into earlier mortality ( Figure 2 ).

Our work evidenced an opposed impact of anti-SARS-CoV-2 S antibodies and viral RNA load or antigenaemia in the mortality risk of critically ill COVID-19 patients. While levels of both IgG and IgM anti-SARS-CoV-2 S antibodies were positively associated with increased survival, the presence of viral components in plasma (RNA or N-antigen) predicted a higher risk of death.

Our study is the largest one to the current date in profiling anti-SARS-CoV-2 S antibodies in critically ill COVID-19 patients, suggesting a protective role of endogenous anti-S antibodies against mortality in these patients. Fourati et al, in a small study with 25 ICU patients, found that patients who were still alive at day-28 displayed significantly higher anti-S1 IgA or IgG titers upon admission than those who had died [8] . Asif et al reported that plasma concentrations of anti-S1 IgA, IgG and IgM antibodies tended to be higher in COVID-19 patients who survived, at both early and late timepoints following ICU admission [9] . Nonetheless, this work involved only 19 patients.

Previous studies have shown that critical COVID-19 patients develop higher titers of SARS-CoV-2 antibodies than those with milder disease, suggesting that antibody response alone is insufficient to avoid severe disease [10] . Our results support nonetheless that critical COVID-19 patients would need to mount a robust anti-S antibody response to survive.

In turn, the connection between viral RNAemia and mortality in COVID-19 has been demonstrated in a metanalysis from Tang et al, involving 2181 patients of different severity [11] . In ICU-COVID-19 patients, Gutmann et al have recently reported that SARS-CoV-2 RNAemia is associated with higher 28-day mortality [12] . Our work identifies the levels of viral RNA in plasma predicting fatal outcomes. As far as we know, this is the first study demonstrating that the presence of antigenaemia is also an independent predictor of mortality in critically ill COVID-19 patients.

The inverse association found between levels of anti-SARS-CoV-2 S antibodies with viral RNA load/antigenaemia suggests that these antibodies could be mediating their beneficial effects (at least in part) by contributing to the control of viral replication and preventing systemic dissemination of the virus or viral components. In this regard, whether the presence of viral RNA/antigens in plasma of severe COVID-19 patients corresponds to the presence of infective viral particles is currently unknown, but spreading of viral material at the systemic level could by itself stimulate innate immunity through TLR or pattern recognition receptors leading to unabated pro-inflammatory responses, which could contribute to the pathogenesis of multi-organ failure in severe COVID-19 [13] . In this regard, it has been described that viral RNA load in plasma and antigenaemia are associated with increased levels of cytokines or C-reactive protein in COVID-19 [3, 7] . The potential role of anti-SARS-CoV-2 S antibodies in the control of viral replication/spreading is also suggested by the results from Röltgen et al, who found that the appearance of these antibodies correlated with a decrease in viral RNAemia along the course of COVID-19 [14] . In turn, Li et al found higher anti-S IgG levels in those recovered patients who were SARS CoV-2 RNA negative in respiratory samples than those who were RNA positive [15] . Lucas et al reported that a delayed seroconversion correlates with impaired viral control and mortality in COVID-19 [16] . In our cohort, patients with the lowest antibody titers were those more promptly admitted to the ICU since the onset of the symptoms, which suggests their inability to timely mount effective humoral responses. Our patients with no anti-SARS-CoV-2 S antibodies at ICU admission showed more often antigenaemia, further supporting a protective role of these antibodies in preventing the dissemination of the virus or viral components. In a small study with 39 (critically and non-critically ill) patients, Ogata et al observed that seroconversion was followed by antigen clearance in plasma [6] . Also, recent findings from Hingrat et al support the implication of anti-SARS-CoV-2 antibodies in the clearance of antigenaemia [17] .

Our findings pose several potential translational implications. 1) Profiling anti-SARS-CoV-2 S antibodies following ICU admission could contribute to personalizing treatment with exogenous antibodies targeting the S protein of the virus and perhaps with convalescent serum [18, 19] . Results from the RECOVERY trial support this notion since only the patients with an absence of anti-S antibodies seem to receive clinical benefit from exogenous monoclonal antibodies against the SARS-CoV-2 Sprotein [18] . 2) Quantification of viral RNA load in plasma could be helpful to identify those COVID-19 patients at risk of suffering a fatal outcome. 3) Profiling antigenaemia using point of care tests could also contribute to early identify those patients at risk of clinical deterioration.

A limitation of our work was that we profiled antibodies, viral RNA load and antigenaemia on samples preserved from the first pandemic wave. The findings reported here should be confirmed with prospective studies with patients from subsequent waves. Another limitation is that we did not evaluate the neutralization activity of anti-SARS-CoV-2 S antibodies. Further studies should clarify if the quantitative results provided here correlate with the functional ability of these antibodies to block viral replication.

Low anti-SARS-CoV-2 S antibody levels predict mortality in critical COVID-19. Our findings support that these antibodies contribute to prevent systemic dissemination of SARS-CoV-2.

The landscape of antibody binding in SARS-CoV-2 infection

An update to monoclonal antibody as therapeutic option against COVID-19

Viral RNA load in plasma is associated with critical illness and a dysregulated host response in COVID-19

Highly sensitive quantification of plasma SARS-CoV-2 RNA shelds light on its potential clinical value

SARS-CoV-2 RNA in serum as predictor of severe outcome in COVID-19: a retrospective cohort study

Ultra-sensitive Serial Profiling of SARS-CoV-2 Antigens and Antibodies in Plasma to Understand Disease Progression in COVID-19 Patients with Severe Disease

Serum levels of SARS-CoV-2 nucleocapsid antigen associate with inflammatory status and disease severity in COVID-19 patients

SARS-CoV-2 viral loads and serum IgA/IgG immune responses in critically ill COVID-19 patients

Weak anti-SARS-CoV-2 antibody response is associated with mortality in a Swedish cohort of COVID-19 patients in critical care

Potent SARS-CoV-2-Specific T Cell Immunity and Low Anaphylatoxin Levels Correlate With Mild Disease Progression in COVID-19 Patients

Quantitative assessment of SARS-CoV-2 RNAemia and outcome in patients with coronavirus disease 2019

SARS-CoV-2 RNAemia and proteomic trajectories inform prognostication in COVID-19 patients admitted to intensive care

COVID 19: a clue from innate immunity

Defining the features and duration of antibody responses to SARS-CoV-2 infection associated with disease severity and outcome

Dynamic changes in anti-SARS-CoV-2 antibodies during SARS-CoV-2 infection and recovery from COVID-19

Delayed production of neutralizing antibodies correlates with fatal COVID-19

Detection of SARS-CoV-2 N-antigen in blood during acute COVID-19 provides a sensitive new marker and new testing alternatives

Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Hyperimmune anti-COVID-19 IVIG (C-IVIG) Therapy for Passive Immunization of Severe and Critically Ill COVID-19 Patients: A structured summary of a study protocol for a randomised controlled trial

Group for Biomedical Research in Sepsis (BioSepsis), Instituto de Investigación Biomédica de Salamanca, (IBSAL)

Institut D investigacions August Pi I Sunyer (IDIBAPS), Carrer del Rosselló

ATORRES@clinic.cat)

We would like to thank the IBSAL and CIBER for administrative support to run this study.

The authors declare that they have no competing interests 

The data that support the findings of this study are available from the corresponding author upon reasonable request.

Vaccinology and Inflammation, and the "Subvenciones de concesión directa para proyectos y programas de investigación del virus SARS-CoV2, causante del COVID-19", FONDO -COVID19, Instituto de Salud Carlos III (COV20/00110, CIBERES, 06/06/0028), (Antoni Torres) and finally by the "Convocatoria extraordinaria y urgente de la Gerencia Regional de Salud de Castilla y León, para la financiación de proyectos de investigación en enfermedad COVID-19" (GRS COVID 53/A/20) (CA). Ana P. Tedim was funded by the Sara Borrell Research Grant CD018/0123 funded by Instituto de Salud Carlos III and co-financed by the European Development Regional Fund (A Way to Achieve Europe programme). The funding sources did not play any role neither in the design of the study and collection, not in the analysis, in the interpretation of data or in writing the manuscript.